Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Merus’ Zenocutuzumab, a HER2/HER3 bispecific antibody, has received FDA accelerated approval for treating advanced pancreatic and lung cancers with NRG1 fusions, marking a breakthrough in cancer treatment. This innovative therapy offers new insights into dynamic signaling regulation and bispecific antibody development.
Zenocutuzumab's FDA approval for NRG1 fusion-driven cancers ends a 30-year gap in HER3-targeted therapies, demonstrating strong efficacy in advanced pancreatic and lung cancers. Discover Creative Biogene's bispecific antibody development services today.
A new review in Journal of Biological Engineering highlights groundbreaking advancements in high-throughput monoclonal antibody screening, reducing discovery cycles from months to days. With cutting-edge platforms like phage display, single-cell sequencing, and AI integration, researchers can now achieve rapid, precise antibody development at unprecedented scale.
The development of corresponding kinase inhibitors to target protein kinases that play a key role in the formation of diseases has become an important means of treating these kinase-related diseases, especially in the field of cancer treatment. Given that phosphorylation regulates many biological processes, protein kinase inhibitors can be used to treat diseases caused by overactive protein kinases or to regulate cell function to overcome other disease drivers.
Antibody fusion proteins (AFPs) are modular engineered biologics that combine the targeting specificity of antibodies with the biological activity of cytokines, enzymes, ligands, or toxins. Through genetic fusion into a single recombinant molecule, AFPs enable precise payload delivery to defined cells or tissues while enhancing stability, pharmacokinetics, and overall therapeutic performance.
Copyright © 2026 Creative Biogene. All rights reserved.